Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,759
  • Shares Outstanding, K 73,399
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,100 K
  • 60-Month Beta 2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.75
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +6.87%
on 11/10/23
1.7500 -20.00%
on 11/27/23
-0.1700 (-10.83%)
since 11/08/23
3-Month
1.3100 +6.87%
on 11/10/23
2.3450 -40.30%
on 09/12/23
-0.8400 (-37.50%)
since 09/08/23
52-Week
1.0900 +28.44%
on 04/11/23
3.3942 -58.75%
on 06/23/23
-0.3200 (-18.60%)
since 12/08/22

Most Recent Stories

More News
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 63.25 (-0.41%)
ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
DSNKY : 27.5700 (-2.34%)
GILD : 79.02 (+1.24%)
ARAY : 2.65 (unch)
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
EXEL : 22.00 (+0.05%)
MRTX : 56.49 (-0.35%)
LLY : 598.05 (+1.66%)
PNT : 14.06 (+0.79%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 63.25 (-0.41%)
ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
DSNKY : 27.5700 (-2.34%)
GILD : 79.02 (+1.24%)
ARAY : 2.65 (unch)
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
BMY : 50.31 (+0.30%)
GILD : 79.02 (+1.24%)
MRK : 103.75 (-0.13%)
PFE : 28.78 (+0.52%)
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response   San Diego, CA, and Calgary, AB – November 9, 2023 –...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent...

ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.4720
2nd Resistance Point 1.4460
1st Resistance Point 1.4230
Last Price 1.4000
1st Support Level 1.3740
2nd Support Level 1.3480
3rd Support Level 1.3250

See More

52-Week High 3.3942
Fibonacci 61.8% 2.5140
Fibonacci 50% 2.2421
Fibonacci 38.2% 1.9702
Last Price 1.4000
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar